Lunella Biotech

Lunella Biotech is a Canadian biotechnology company focused on extending human healthspan and lifespan by targeting the metabolic vulnerabilities of cancer stem cells and senescent cells. An affiliate of the Canadian Bank Note Company, the firm utilizes a proprietary mitochondrial-based oncology platform (MITO-ONC-RX) to develop novel therapeutics, including Mitoriboscins and Repurposcins. Their research emphasizes drug repurposing and the inhibition of mitochondrial biogenesis to eradicate treatment-resistant cancer cells and reverse the effects of aging. Led by renowned scientists Michael P. Lisanti and Federica Sotgia, Lunella Biotech is advancing a pipeline of small molecule inhibitors targeting mitochondrial ribosomes, POLRMT, and CDK 4/6.